Modern perspectives on the clinical features of psoriasis with comorbidities: a review

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The rising prevalence of psoriasis and the gradual elucidation of new etiopathogenetic mechanisms have intensified interest in studying this dermatosis across various clinical contexts, including in the presence of comorbidities. Accumulating evidence indicates that shared pathogenic pathways between psoriasis and several systemic diseases contribute to increased disease burden, reduced therapeutic responsiveness, shorter remission periods, and a heightened risk of severe forms of psoriasis—namely, psoriatic arthritis and erythroderma. Particular attention in this review is devoted to psoriasis in combination with metabolic syndrome, a condition characterized by overweight/obesity, hypertension, and disturbances in carbohydrate and lipid metabolism.

This review summarizes current research examining the association between psoriasis and comorbidities—including metabolic syndrome, cardiovascular diseases, and others. Comorbidities in psoriasis underscore the close interconnection among body systems, highlighting the importance of targeted evaluation of patients to assess the risk of cardiovascular disease, endocrine disorders, and other conditions. Such an approach may improve both life expectancy and quality of life in this population.

About the authors

Natalya A. Simakova

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Skin and Venereal Diseases Dispensary No. 1

Author for correspondence.
Email: evseevanatasha@yandex.ru
ORCID iD: 0000-0003-3222-145X
SPIN-code: 2365-9085
Russian Federation, Krasnoyarsk; Krasnoyarsk

Yuri Y. Vinnik

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University; Krasnoyarsk Regional Skin and Venereal Diseases Dispensary No. 1

Email: vinnik33@mail.ru
ORCID iD: 0000-0002-8135-0445
SPIN-code: 7946-6230

MD, Dr. Sci. (Medicine), Assistant Professor

Russian Federation, Krasnoyarsk; Krasnoyarsk

Pavel A. Shesternya

Professor V.F. Voino-Yasenetsky Krasnoyarsk State Medical University

Email: sci-prorector@krasgmu.ru
ORCID iD: 0000-0001-8652-1410
SPIN-code: 6527-8762

д-р мед. наук, профессор

Russian Federation, Krasnoyarsk

References

  1. Psoriasis. Clinical guidelines. Russian society of dermatologists and cosmetologists; 2019. 46 p. (In Russ.)
  2. Kubanov AA, Bogdanova EV. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik dermatologii i venerologii. 2019;95(4):8–13. doi: 10.25208/0042-4609-2019-95-4-8-23 EDN: GPRIJE
  3. Pritulo OA, Rychkova IV. Current understanding of the pathogenesis of psoriasis. Tavricheskiy mediko-biologicheskiy vestnik. 2017;20(1):141–153. (In Russ.) EDN: YUBZKJ
  4. Dontsova EV, Olisova OYu, Kruglova LS. Psoriasis and metabolic syndrome: comorbidity mechanisms. Medical alphabet. 2019;1(7):34–38. doi: 10.33667/2078-5631-2019-1-7(382)-34-38 EDN: NDYPYT
  5. Rosete-Pidal EA, Kruglova LS, Ponich ES, et al. Preparations in treatment of psoriasis patients with concurrent metabolic syndrome: Efficiency predictors and potential risks (review of literature). Russian journal of Occupational health and industrial ecology. 2017;(8):33–36. EDN: ZFMFKH
  6. Lykova SG, Morzhanaeva MA, Nemchaninova OB, Svechnikova EV. Psoriasis in patients with metabolic syndrome: Clinical aspects of the problem. Russian journal of Clinical dermatology and venereology. 2020;19(2):214–222. doi: 10.17116/klinderma202019021214 EDN: YEFINL
  7. Markina EV, Vorvul AO, Vatutina AS, Svetyi LI. Relationship between psoriasis severity and metabolic syndrome severity. In: Molodezh’--prakticheskomu zdravookhraneniyu: XIII All-Russian Scientific Conference of Medical Students and Young Scientists with International Participation, Ivanovo, Nov 13. Ivanovo; 2019. Р. 100–107. (In Russ.) EDN: PSPZFM
  8. Murashkin NN, Kruglova LS, Kovalenko IuA, et al. Psoriasis comorbidities in childhood. Current pediatrics. 2020;19(6):460–467. doi: 10.15690/vsp.v19i6.2149 EDN: STSOQE
  9. Nemchaninova OB, Sklyanova EYu, Lykova SG, et al. Comorbidity: Non-alcoholic fatty liver disease and psoriasis. Experimental & clinical gastroenterology. 2021;(10):55–60. doi: 10.31146/1682-8658-ecg-194-10-55-60 EDN: BORAXZ
  10. Batkaeva NV, Korotaeva TV, Batkaev EA. Multiplicity of comorbidities in patients with severe psoriasis. Almanac of clinical medicine. 2018;46(1):76–81. doi: 10.18786/2072-0505-2018-46-1-76-81 EDN: YVSHIM
  11. Sosnova EA. Metabolic syndrome. V.F. Snegirev archives of obstetrics and gynecology. 2016;3(4):172–180. doi: 10.18821/2313-8726-2016-3-4-172-180 EDN: XGVDHJ
  12. Recommendations on the management of patients with metabolic syndrome: Clinical recommendations. Moscow; 2013. 42 р. (In Russ.)
  13. Mehrdad M, Doaei S, Gholamalizadeh M, et al. Association of FTO rs9939609 polymorphism with serum leptin, insulin, adiponectin, and lipid profile in overweight adults. Adipocyte. 2020;9(1):51–56. doi: 10.1080/21623945.2020.1722550
  14. Bondareva EA, Zadorozhnaya LV, Khomyakova IA. T/A polymorphism of the FTO gene and lifestyle are associated with fat accumulation in different age groups of men. Obesity and metabolism. 2019;16(2):49–53. doi: 10.14341/omet9798 EDN: CGNJGL
  15. Khobeysh M, Sysoev KA, Sokolovskiy EV, Lapin SV. The role of adipokines and cytokines in the pathogenesis of psoriasis in patients with concomitant metabolic disorders. Kremlin medicine. Clinical bulletin. 2018;(1):26–35. EDN: YQXTSU
  16. Dontsova E, Novikova LA. Comparative indicators’’ characteristic of oxidative stress in patients with psoriasis of varying severity and metabolic syndrome. Kremlin medicine. Clinical bulletin. 2018;(1):45–48. EDN: YQXTTV
  17. Singh S, Young P, Armstrong AW. An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies. PLoS One. 2017;12(7):e0181039. doi: 10.1371/journal.pone.0181039
  18. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol. 2007;157(1):68–73. doi: 10.1111/j.1365-2133.2007.07986.x
  19. Gurbo OP, Frolova OI, Kovkova GYu, et al. The effect of metabolic syndrome on changes in the indicators of trace microelemental status and lipid peroxidation system in patients with psoriasis vulgaris. Medical science and education of Ural. 2021;22(4):34–37. doi: 10.36361/1814-8999-2021-22-4-34-37 EDN: RYWMFV
  20. Panshina NN, Shilova LN. Clinical features of metabolic syndrome in patients with psoriatic arthritis. Volgogradskii nauchno-meditsinskii zhurnal. 2017;(1):31–33. EDN: ZIOOET
  21. Srinivas S, Nagendra S, Kashinath RT. Alterations in plasma lipid profile and cardiovascular risk indicators in clinically sub-grouped psoriasis. Int J Res Dermatol. 2019;5(2):2455–4529. doi: 10.18203/issn.2455-4529.IntJResDermatol20190429
  22. Egeberg A, Skov L, Joshi AA, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650–656. doi: 10.1016/j.jaad.2017.06.028
  23. Hotko AA, Pomazanova MYu, Kozyr YV. Diseases of cardiovascular system in patients with severe and moderate-severe forms of psoriasis. Medical alphabet. 2021;(9):21–23. doi: 10.33667/2078-5631-2021-9-21-23 EDN: JQHOVP
  24. Kondratieva YS, Vedler AA. Adherence of patients with psoriasis and concomitant diseases of the circulatory system to pharmacotherapy and healthy lifestyle. Dermatology in Russia. 2017;(S1):54–55. (In Russ.) EDN: XHRIJG
  25. Nemchaninova OB, Pavlova TG, Pozdnjakova ON, et al. The influence of individual lifestyle components on the severity of clinical course in patients with psoriasis in Kemerovo region. Medical almanac. 2018;52(1):130-132. (In Russ.)
  26. Doncova EV, Kruglova LS, Olisova OU. Combined therapy of psoriasis occurring in the background of the metabolic syndrome. Vestnik novyh medicinskih tekhnologii. 2018;(6):253–260. doi: 10.24411/2075-4094-2018-16300 EDN: YRKLAT
  27. Bakulev AL. Clinical features of psoriasis, risk factors and associated comorbidity. Clinical pharmacology and therapy. 2019;28(1):35–39. EDN: FCQAVV
  28. Agranovsky ML, Rakhmatov AB, Makhmutov RKh. Comorbidity of neurotic disorders with major pathology in patients with psoriasis. Epomen: Medical sciences. 2022;(2):6–18. EDN: FOILMR
  29. Kovalyova YuS, Vedler AA, Subbotin EA, Gribova GV. Psoriatic onychodystrophy as a marker of psoriasis severity and concomitant comorbidity. Vestnik Surgutskogo gosudarstvennogo universiteta. Meditsina. 2020;(4):51–57. doi: 10.34822/2304-9448-2020-4-51-57 EDN: THEJXU
  30. Lykova SG, Spitsyna AV, Morzhanaeva MA. Metabolic syndrome and psoriasis are as comorbidity states. Far Eastern medical journal. 2017;(1):93–98. EDN: YIXPAJ
  31. Borska L, Kremlacek J, Andrys C, et al. Systemic inflammation, oxidative damage to nucleic acids, and metabolic syndrome in the pathogenesis of psoriasis. Int J Mol Sci. 2017;18(11):2238. doi: 10.3390/ijms18112238
  32. Valiev AA, Khaitov KN, Turdieva ShT. Diapason of concomitant diseases in children with psoriasis. Medical council. 2022;16(3):56–62. doi: 10.21518/2079-701X-2022-16-3-56-62 EDN: PLBENG
  33. Tereshchenko GP, Levkova EA, Savin SZ. Theoretical and practical aspects of psoriasis in paediatric practice. Tendentsii razvitiya nauki i obrazovaniya. 2022;(88-1):108–113. (In Russ.) doi: 10.18411/trnio-08-2022-32 EDN: QQVLGK

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Eco-Vector

License URL: https://eco-vector.com/for_authors.php#07
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).